Biopharma Layoff Tracker 2026: Novo, GSK and Pfizer Drive Deep Cuts

Novo Nordisk has shed roughly 13,000 employees over the past year, CEO Mike Maziar Doustdar confirmed on Sept. 21, leaving the Danish pharma with about 67,000 staff worldwide. That figure anchors a 2026 layoff season in which GSK is cutting more than 1,850 roles in Europe alone, Pfizer has added $2.5 billion to its restructuring savings target, and at least a dozen clinical-stage biotechs have gutted their workforces after late-stage trial failures.

The pattern is consistent across the tracker: failed Phase 3 readouts trigger deep cuts within weeks, and Big Pharma cost programs—GSK's $2.5 billion plan, Merck's $3 billion campaign, Takeda's $1.25 billion transformation—keep whittling manufacturing and support functions. For R&D managers, the signal is blunt: discovery and non-core programs are the first line items on the chopping block.

What is driving the biggest cuts?

GSK's three-year, $2.5 billion restructuring hit Belgium hardest in October, with up to 1,217 roles cut across Rixensart, Wavre and Gembloux sites, following roughly 650 job losses from the closure of its Dresden vaccine manufacturing campus. CEO Luke Miels framed the logic plainly: "I want people at the bench in the lab or out there talking to physicians or on the line in a manufacturing environment."

Pfizer added $2.5 billion to its ongoing cost program in August, with savings targeted at $1 billion, primarily between 2027 and 2029, at a one-time cost of $2 billion for severance and digital initiatives. Reported cuts include roughly 330 jobs in Sicily, about 150 in Portage, Michigan, and undisclosed numbers at Rocky Mount and Sanford, North Carolina manufacturing sites—part of what a spokesperson called regular "evaluations focused on operational efficiencies."

Novo's 13,000-person reduction includes the 9,000 layoffs announced in September 2025 to generate $1.25 billion in annualized savings, plus 4,000 additional exits spanning retirements, attrition and voluntary departures. In April, Novo cut about 400 jobs at its Bloomington, Indiana plant—part of the former Catalent network acquired for $16.5 billion—leaving roughly 1,400 workers there after FDA flagged contamination issues.

Which trial failures triggered biotech restructurings?

Ultragenyx is cutting about 20% of its workforce—roughly 250 people, leaving approximately 1,000 employees—as it pivots to commercial execution behind two newly approved gene therapies, Genglycos and Fayuvi, and a "smaller, more targeted R&D footprint." The company expects R&D expenses below $350 million in 2027. The move follows the Phase 3 failure of Angelman syndrome therapy apazunersen in September, which sent shares down more than 43%.

EyePoint is cutting 53% of its workforce—105 employees—after duravyu failed again against Regeneron's Eylea in the Phase 3 Lucia wet AMD trial, prompting early termination of pivotal studies and a pivot to diabetic macular edema. Caribou Biosciences, co-founded by Jennifer Doudna, is discontinuing its entire clinical-stage pipeline and laying off 87 of its 97 employees effective Dec. 7, with restructuring costs of $15 million to $19 million. CEO Rachel Haurwitz wrote that the financing environment for allogeneic CAR-T "has made it impossible to secure the capital required."

The list continues: Artiva Biotherapeutics is wiping out 94% of its workforce after two patient deaths in AlloNK trials; ADC Therapeutics cut 17% of staff after 27 deaths in the Zynlonta arm of LOTIS-5; Replimune shed 224 Massachusetts employees after the FDA's second rejection of RP1; and Fulcrum cut 85% of staff after dropping its sickle cell candidate pociredir amid FDA benefit-risk concerns.

What do the deals and shutdowns show?

Post-acquisition integration drove several rounds. Gilead laid off 192 Arcellx employees—roughly 87% of that biotech's staff—after closing its $7.8 billion acquisition. Novartis-owned Avidity is cutting 40 San Diego employees eight months after the acquisition closed. Sanofi's Blueprint Medicines is letting go of 229 Cambridge employees, about a third of its workforce.

Full shutdowns include Sangamo (bankruptcy, 51 layoffs, with Eli Lilly and Astellas placing stalking horse bids), IO Biotech (Chapter 7), Tempero Bio (after a serious adverse event in a Phase 2 alcohol use disorder trial), and Nido Biosciences, which raised $109 million in 2023 but is closing after NIDO-361 missed in Phase 2.

What savings are companies actually booking?

The numbers vary sharply. Vistagen's second round of cuts—31% of remaining staff, about 13 people—will cost $1 million in severance and save $3.2 million annually. Theravance expects its 50% reduction to cut operating expenses 60%, generating $60 million to $70 million in annualized cash flow. aTyr's 60% cut will save $13 million annually and extend its runway into late 2028. At the other end, LENZ Therapeutics is cutting 75% of staff, losing CEO Eef Schimmelpennink, and absorbing $5 million in charges as its stock sits down nearly 80% year-to-date.

Takeda's transformation program will cut some 4,500 roles in fiscal 2026—under 10% of its global workforce, with 2,200 open roles prioritized for internal candidates, the company said. Bristol Myers Squibb continues its New Jersey purge with 265 more Princeton layoffs through May 2027, and Novartis has disclosed at least 922 job cuts in 2026, including 572 at East Hanover alone.

With GSK declining to quantify remaining global cuts and Pfizer not confirming headcount impacts, the 2027 totals will almost certainly grow.